XTSXRX
Market cap93mUSD
Dec 24, Last price
11.55CAD
1D
-0.86%
1Q
5.00%
Jan 2017
44.38%
Name
Biosyent Inc
Chart & Performance
Profile
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 31,590 13.12% | 27,925 -2.42% | 28,618 28.15% | |||||||
Cost of revenue | 23,354 | 20,567 | 19,913 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 8,236 | 7,358 | 8,705 | |||||||
NOPBT Margin | 26.07% | 26.35% | 30.42% | |||||||
Operating Taxes | 2,074 | 1,972 | 2,097 | |||||||
Tax Rate | 25.18% | 26.81% | 24.09% | |||||||
NOPAT | 6,162 | 5,386 | 6,608 | |||||||
Net income | 6,460 18.35% | 5,458 -13.11% | 6,282 65.51% | |||||||
Dividends | (1,913) | (484) | ||||||||
Dividend yield | 1.70% | 0.55% | ||||||||
Proceeds from repurchase of equity | (3,629) | (3,649) | (1,838) | |||||||
BB yield | 3.23% | 4.16% | 1.73% | |||||||
Debt | ||||||||||
Debt current | 183 | 174 | 162 | |||||||
Long-term debt | 2,259 | 2,616 | 2,952 | |||||||
Deferred revenue | (1,403) | |||||||||
Other long-term liabilities | 1,403 | |||||||||
Net debt | (26,245) | (26,164) | (25,281) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 5,055 | 4,949 | 4,675 | |||||||
CAPEX | (174) | (519) | (93) | |||||||
Cash from investing activities | 884 | (10,790) | (4,837) | |||||||
Cash from financing activities | (5,785) | (4,371) | (2,076) | |||||||
FCF | 4,852 | 4,634 | 4,946 | |||||||
Balance | ||||||||||
Cash | 26,187 | 28,696 | 28,212 | |||||||
Long term investments | 2,500 | 258 | 183 | |||||||
Excess cash | 27,107 | 27,558 | 26,964 | |||||||
Stockholders' equity | 32,473 | 31,134 | 29,736 | |||||||
Invested Capital | 8,873 | 6,882 | 6,049 | |||||||
ROIC | 78.23% | 83.30% | 142.94% | |||||||
ROCE | 22.77% | 21.25% | 26.30% | |||||||
EV | ||||||||||
Common stock shares outstanding | 12,170 | 12,541 | 12,871 | |||||||
Price | 9.22 31.71% | 7.00 -15.25% | 8.26 4.42% | |||||||
Market cap | 112,211 27.83% | 87,784 -17.43% | 106,317 2.65% | |||||||
EV | 85,966 | 61,621 | 81,036 | |||||||
EBITDA | 8,691 | 7,809 | 9,162 | |||||||
EV/EBITDA | 9.89 | 7.89 | 8.84 | |||||||
Interest | 68 | 77 | 85 | |||||||
Interest/NOPBT | 0.83% | 1.05% | 0.98% |